Skip to main content

Skin Wound

0
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
human umbilical cord mesenchymal stem cellsN/A1 trial
Active Trials
NCT05984628Recruiting88Est. Oct 2026
Cutiss
CutissSwitzerland - Schlieren
1 program
EHSG-KFPHASE_21 trial
Active Trials
NCT03394612Active Not Recruiting20Est. Dec 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CutissEHSG-KF
UNION therapeuticshuman umbilical cord mesenchymal stem cells

Clinical Trials (2)

Total enrollment: 108 patients across 2 trials

Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Full-Thickness Skin Defects in Adults and Children

Start: Feb 2018Est. completion: Dec 202620 patients
Phase 2Active Not Recruiting
NCT05984628UNION therapeuticshuman umbilical cord mesenchymal stem cells

Umbilical Cord Stem Cells for Skin Grafts in Donor Site Wounds

Start: Oct 2021Est. completion: Oct 202688 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 108 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.